Paroxysmal Nocturnal Hemoglobinuria Market

Paroxysmal Nocturnal Hemoglobinuria Market (Treatment: Medication, Supplements, Blood Transfusion, Bone Marrow Transplant, and Immunosuppressive Therapy; and End-user: Hospitals & Clinics, Homecare Settings, and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2024-2034

Paroxysmal Nocturnal Hemoglobinuria Market Outlook 2034

  • The global industry was valued at US$ 3.8 Bn in 2023
  • It is expected to grow at a CAGR of 10.8% from 2024 to 2034 and reach US$ 11.7 Bn by the end of 2034

Analyst Viewpoint

Rise in geriatric population and influx of biologics are augmenting the paroxysmal nocturnal hemoglobinuria market demand. Paroxysmal nocturnal hemoglobinuria (PNH) is a chronic disorder affecting nearly 20,000 people across the globe. It is characterized by three major manifestations, i.e. pancytopenia, persistent intravascular hemolysis, and thrombosis.

Companies spanning the paroxysmal nocturnal hemoglobinuria market report scope are working toward adoption of oral Iptacopan monotherapy in PNH. They are also exploring research opportunities regarding management of residual anemia in paroxysmal nocturnal hemoglobinuria.

Influx of injectors approved by the regulatory bodies is expected to open new arenas for the stakeholders to map strategies for dealing with paroxysmal nocturnal hemoglobinuria.

Paroxysmal Nocturnal Hemoglobinuria Market Overview

Paroxysmal nocturnal hemoglobinuria (PNH) means a rare blood disorder that occurs when one’s immune system partly attacks as well as damages the platelets and red blood cells. If left untreated, PNH is likely to result in chronic kidney disease or thrombosis (blood clots) or hemolytic anemia.

The symptom of PNH constitutes dark/brown/red urine early morning or during late night. ‘Paroxysmal’ means ‘sudden’, ‘nocturnal’ means ‘night’, and ‘hemoglobinuria’ means pee stained with blood.

Soliris (eculizumab) is the first drug approved for treating patients suffering from PNH by curtailing hemolysis. This monoclonal antibody reduces/terminates need for blood transfusions.

At present, there are over 16 products at various stages for treating PNH. On clinical success, they ought to generate noticeable revenue.

Attribute Detail
Market Drivers
  • Increase in Geriatric Population
  • Emergence of Biologics

Rise in Geriatric Population Propelling Paroxysmal Nocturnal Hemoglobinuria Interventions

Paroxysmal nocturnal hemoglobinuria (PNH) is a type of clonal disorder that is generally associated with failure of the bone marrow, and in rare instances it may result in leukemia as well.

Age-related clonal hematopoiesis (ARCH) is likely to be the critical link between development of cancer and PNH.

As per the United Nations, percentage of individuals aged 65 and above is expected to rise to 16% by 2050 from 10% in 2022. It further states that the year 2050 is bound to witness twice the number of individuals in the age group of 65 and above the number of children aged 5 and below.

Rise in geriatric population is thus accelerating the paroxysmal nocturnal hemoglobinuria market opportunities.

Emergence of Biologics Driving Demand for Management of Paroxysmal Nocturnal Hemoglobinuria

Biologics is a class of medicines grown in genetically engineered cell cultures. They have reported to transform management of several cancers as well as rare diseases such as paroxysmal nocturnal hemoglobinuria.

Due to increase in spending on prescription drugs coupled with expiry of patents, the manufacturers of drugs have come up with biosimilars, i.e. biologics that are more affordable and analogous to licensed biological therapeutics.

Biosimilars are seen obtaining regulatory approvals across the globe and widening the access of patients to biologics.

Biologics include blood products, hormones, cytokines, vaccines, growth factors, and monoclonal antibodies. They are looked upon as indispensable options regarding treatment of cancer and various other health conditions.

Continual emergence of biologics to cater to therapeutic approaches to paroxysmal nocturnal hemoglobinuria is thus expanding the paroxysmal nocturnal hemoglobinuria market size.

Regional Outlook

Attribute Detail
Leading Region North America

As per the latest paroxysmal nocturnal hemoglobinuria market analysis, North America dominated the paroxysmal nocturnal hemoglobinuria care landscape in 2023 and the dominance is expected to continue during the forecast period. This is attributed to the U.S. witnessing speedy approvals of drugs followed by adoption of new therapies.

Soliris targets the CD5 complement component and dramatically lessens pain linked with symptoms such as abdominal pain, easy bleeding, weakness, dark urine, and fatigue.

Asia Pacific is also holding a decent paroxysmal nocturnal hemoglobinuria market share. Its significant paroxysmal nocturnal hemoglobinuria industry growth is ascribed to Japan witnessing a rising adoption of new therapies.

Analysis of Key Players

The prominent players pertaining to treatment for paroxysmal nocturnal hemoglobinuria are devising new products and also working toward upgradation of the existing ones in order to make a mark in the paroxysmal nocturnal hemoglobinuria market.

For instance, in June 2024, Kira Pharmaceuticals presented positive results of KP104 Phase 2 PNH study at the European Hemotology association (EHA) Congress 2024.

Alexion Pharmaceuticals, Inc., Apellis Pharmaceuticals, Genentec, Inc., Novartis AG, The Takeda Pharmaceutical Company Limited, Kira Pharmaceuticals, F. Hoffman-La Roche AG, Akari Therapeutics PLC, Omeros Corporation, and Regeneron Pharmaceuticals, Inc. are some of the key participants covered in the paroxysmal nocturnal hemoglobinuria market report.

These companies have been profiled based on parameters such as company overview, business strategies, financial overview, product portfolio, and business segments.

Paroxysmal Nocturnal Hemoglobinuria Market Competitive Landscape Analysis

  • In August 2022, Amgen announced positive top-line results from a double-blind, randomized, two-period crossover, active-controlled Phase 3 study called DAHLIA study in order to evaluate safety and efficacy of ABP 959, a biosimilar candidate to SOLIRIS (eculizumab) in comparison with SOLIRIS in adults suffering from paroxysmal nocturnal hemoglobinuria (PNH).

Global Paroxysmal Nocturnal Hemoglobinuria Market Snapshot

Attribute Detail
Market Size in 2023 US$ 3.8 Bn
Market Forecast (Value) in 2034 US$ 11.7 Bn
Growth Rate (CAGR) 10.8%
Forecast Period 2024-2034
Historical Data Available for 2020-2022
Quantitative Units US$ Bn for Value
Market Analysis It includes segment analysis as well as regional level analysis. Moreover, qualitative analysis includes drivers, restraints, opportunities, key trends, Porter’s Five Forces analysis, value chain analysis, and key trend analysis.
Competition Landscape
  • Market share analysis by company (2023)
  • Company profiles section includes overview, product portfolio, sales footprint, key subsidiaries or distributors, strategy & recent developments, and key financials
Format Electronic (PDF) + Excel
Market Segmentation
  • Treatment
    • Medication
      • Eculizumab
      • Ravulizumab
    • Supplements
    • Blood Transfusion
    • Bone Marrow Transplant
    • Immunosuppressive Therapy
  • End-user
    • Hospitals & Clinics
    • Homecare Settings
    • Others (Research Institutes, etc.)
Regions Covered
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa
Countries Covered
  • U.S.
  • Canada
  • Germany
  • U.K.
  • France
  • Italy
  • Spain
  • China
  • India
  • Japan
  • Australia & New Zealand
  • Brazil
  • Mexico
  • South Africa
  • GCC
Companies Profiled
  • Alexion Pharmaceuticals, Inc.
  • Apellis Pharmaceuticals
  • Genentec, Inc.
  • Novartis AG
  • The Takeda Pharmaceutical Company Limited
  • Kira Pharmaceuticals
  • F. Hoffman-La Roche AG
  • Akari Therapeutics PLC
  • Omeros Corporation
  • Regeneron Pharmaceuticals, Inc.
Customization Scope Available Upon Request
Pricing Available Upon Request

Frequently Asked Questions

How big was the global paroxysmal nocturnal hemoglobinuria market in 2023?

It was valued at US$ 3.8 Bn in 2023

How is the paroxysmal nocturnal hemoglobinuria business expected to grow during the forecast period?

It is projected to grow at a CAGR of 10.8% from 2024 to 2034

What are the key factors driving the demand for paroxysmal nocturnal hemoglobinuria?

Growing geriatric population and emergence of biologics

Which paroxysmal nocturnal hemoglobinuria end-user segment held the largest share in 2023?

Hospitals & clinics segment accounted for the largest share in 2023

Which region dominated the global paroxysmal nocturnal hemoglobinuria landscape in 2023?

North America was the dominant region in 2023

Who are the key paroxysmal nocturnal hemoglobinuria manufacturers?

Alexion Pharmaceuticals, Inc., Apellis Pharmaceuticals, Genentec, Inc., Novartis AG, The Takeda Pharmaceutical Company Limited, Kira Pharmaceuticals, F. Hoffman-La Roche AG, Akari Therapeutics PLC, Omeros Corporation, and Regeneron Pharmaceuticals, Inc.

1. Preface

    1.1. Market Definition and Scope

    1.2. Market Segmentation

    1.3. Key Research Objectives

    1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Paroxysmal Nocturnal Hemoglobinuria Market

4. Market Overview

    4.1. Introduction

        4.1.1. Product Definition

        4.1.2. Industry Evolution/Developments

    4.2. Overview

    4.3. Market Dynamics

        4.3.1. Drivers

        4.3.2. Restraints

        4.3.3. Opportunities

    4.4. Global Paroxysmal Nocturnal Hemoglobinuria Market Analysis and Forecast, 2020-2034

5. Key Insights

    5.1. Pipeline Analysis

    5.2. Key Product/Brand Analysis

    5.3. Key Mergers & Acquisitions

    5.4. COVID-19 Pandemic Impact on Industry

6. Global Paroxysmal Nocturnal Hemoglobinuria Market Analysis and Forecast, by Treatment

    6.1. Introduction & Definition

    6.2. Key Findings/Developments

    6.3. Market Value Forecast, by Treatment, 2020-2034

        6.3.1. Medication

            6.3.1.1. Eculizumab

            6.3.1.2. Ravulizumab

        6.3.2. Supplements

        6.3.3. Blood Transfusion

        6.3.4. Bone Marrow Transplant

        6.3.5. Immunosuppressive Therapy

    6.4. Market Attractiveness Analysis, by Treatment

7. Global Paroxysmal Nocturnal Hemoglobinuria Market Analysis and Forecast, by End-user

    7.1. Introduction & Definition

    7.2. Key Findings/Developments

    7.3. Market Value Forecast, by End-user, 2020-2034

        7.3.1. Hospitals & Clinics

        7.3.2. Homecare Settings

        7.3.3. Others (Research Institutes, etc.)

    7.4. Market Attractiveness Analysis, by End-user

8. Global Paroxysmal Nocturnal Hemoglobinuria Market Analysis and Forecast, by Region

    8.1. Key Findings

    8.2. Market Value Forecast, by Region, 2020-2034

        8.2.1. North America

        8.2.2. Europe

        8.2.3. Asia Pacific

        8.2.4. Latin America

        8.2.5. Middle East & Africa

    8.3. Market Attractiveness Analysis, by Region

9. North America Paroxysmal Nocturnal Hemoglobinuria Market Analysis and Forecast

    9.1. Introduction

    9.2. Key Findings

    9.3. Market Value Forecast, by Treatment, 2020-2034

        9.3.1. Medication

            9.3.1.1. Eculizumab

            9.3.1.2. Ravulizumab

        9.3.2. Supplements

        9.3.3. Blood Transfusion

        9.3.4. Bone Marrow Transplant

        9.3.5. Immunosuppressive Therapy

    9.4. Market Value Forecast, by End-user, 2020-2034

        9.4.1. Hospitals & Clinics

        9.4.2. Homecare Settings

        9.4.3. Others (Research Institutes, etc.)

    9.5. Market Value Forecast, by Country, 2020-2034

        9.5.1. U.S.

        9.5.2. Canada

    9.6. Market Attractiveness Analysis

        9.6.1. By Treatment

        9.6.2. By End-user

        9.6.3. By Country

10. Europe Paroxysmal Nocturnal Hemoglobinuria Market Analysis and Forecast

    10.1. Introduction

    10.2. Key Findings

    10.3. Market Value Forecast, by Treatment, 2020-2034

        10.3.1. Medication

            10.3.1.1. Eculizumab

            10.3.1.2. Ravulizumab

        10.3.2. Supplements

        10.3.3. Blood Transfusion

        10.3.4. Bone Marrow Transplant

        10.3.5. Immunosuppressive Therapy

    10.4. Market Value Forecast, by End-user, 2020-2034

        10.4.1. Hospitals & Clinics

        10.4.2. Homecare Settings

        10.4.3. Others (Research Institutes, etc.)

    10.5. Market Value Forecast, by Country/Sub-region, 2020-2034

        10.5.1. Germany

        10.5.2. U.K.

        10.5.3. France

        10.5.4. Italy

        10.5.5. Spain

        10.5.6. Rest of Europe

    10.6. Market Attractiveness Analysis

        10.6.1. By Treatment

        10.6.2. By End-user

        10.6.3. By Country/Sub-region

11. Asia Pacific Paroxysmal Nocturnal Hemoglobinuria Market Analysis and Forecast

    11.1. Introduction

    11.2. Key Findings

    11.3. Market Value Forecast, by Treatment, 2020-2034

        11.3.1. Medication

            11.3.1.1. Eculizumab

            11.3.1.2. Ravulizumab

        11.3.2. Supplements

        11.3.3. Blood Transfusion

        11.3.4. Bone Marrow Transplant

        11.3.5. Immunosuppressive Therapy

    11.4. Market Value Forecast, by End-user, 2020-2034

        11.4.1. Hospitals & Clinics

        11.4.2. Homecare Settings

        11.4.3. Others (Research Institutes, etc.)

    11.5. Market Value Forecast, by Country/Sub-region, 2020-2034

        11.5.1. China

        11.5.2. Japan

        11.5.3. India

        11.5.4. Australia & New Zealand

        11.5.5. Rest of Asia Pacific

    11.6. Market Attractiveness Analysis

        11.6.1. By Treatment

        11.6.2. By End-user

        11.6.3. By Country/Sub-region

12. Latin America Paroxysmal Nocturnal Hemoglobinuria Market Analysis and Forecast

    12.1. Introduction

    12.2. Key Findings

    12.3. Market Value Forecast, by Treatment, 2020-2034

        12.3.1. Medication

            12.3.1.1. Eculizumab

            12.3.1.2. Ravulizumab

        12.3.2. Supplements

        12.3.3. Blood Transfusion

        12.3.4. Bone Marrow Transplant

        12.3.5. Immunosuppressive Therapy

    12.4. Market Value Forecast, by End-user, 2020-2034

        12.4.1. Hospitals & Clinics

        12.4.2. Homecare Settings

        12.4.3. Others (Research Institutes, etc.)

    12.5. Market Value Forecast, by Country/Sub-region, 2020-2034

        12.5.1. Brazil

        12.5.2. Mexico

        12.5.3. Rest of Latin America

    12.6. Market Attractiveness Analysis

        12.6.1. By Treatment

        12.6.2. By End-user

        12.6.3. By Country/Sub-region

13. Middle East & Africa Paroxysmal Nocturnal Hemoglobinuria Market Analysis and Forecast

    13.1. Introduction

    13.2. Key Findings

    13.3. Market Value Forecast, by Treatment, 2020-2034

        13.3.1. Medication

            13.3.1.1. Eculizumab

            13.3.1.2. Ravulizumab

        13.3.2. Supplements

        13.3.3. Blood Transfusion

        13.3.4. Bone Marrow Transplant

        13.3.5. Immunosuppressive Therapy

    13.4. Market Value Forecast, by End-user, 2020-2034

        13.4.1. Hospitals & Clinics

        13.4.2. Homecare Settings

        13.4.3. Others (Research Institutes, etc.)

    13.5. Market Value Forecast, by Country/Sub-region, 2020-2034

        13.5.1. GCC Countries

        13.5.2. South Africa

        13.5.3. Rest of Middle East & Africa

    13.6. Market Attractiveness Analysis

        13.6.1. By Treatment

        13.6.2. By End-user

        13.6.3. By Country/Sub-region

14. Competition Landscape

    14.1. Market Player - Competitive Matrix (by Tier and Size of Companies)

    14.2. Market Share Analysis, by Company (2023)

    14.3. Company Profiles

        14.3.1. Alexion Pharmaceuticals, Inc.

            14.3.1.1. Company Overview

            14.3.1.2. Product Portfolio

            14.3.1.3. SWOT Analysis

            14.3.1.4. Financial Overview

            14.3.1.5. Strategic Overview

        14.3.2. Apellis Pharmaceuticals

            14.3.2.1. Company Overview

            14.3.2.2. Product Portfolio

            14.3.2.3. SWOT Analysis

            14.3.2.4. Financial Overview

            14.3.2.5. Strategic Overview

        14.3.3. Genentec, Inc.

            14.3.3.1. Company Overview

            14.3.3.2. Product Portfolio

            14.3.3.3. SWOT Analysis

            14.3.3.4. Financial Overview

            14.3.3.5. Strategic Overview

        14.3.4. Novartis AG

            14.3.4.1. Company Overview

            14.3.4.2. Product Portfolio

            14.3.4.3. SWOT Analysis

            14.3.4.4. Financial Overview

            14.3.4.5. Strategic Overview

        14.3.5. The Takeda Pharmaceutical Company Limited

            14.3.5.1. Company Overview

            14.3.5.2. Product Portfolio

            14.3.5.3. SWOT Analysis

            14.3.5.4. Financial Overview

            14.3.5.5. Strategic Overview

        14.3.6. Kira Pharmaceuticals

            14.3.6.1. Company Overview

            14.3.6.2. Product Portfolio

            14.3.6.3. SWOT Analysis

            14.3.6.4. Financial Overview

            14.3.6.5. Strategic Overview

        14.3.7. F. Hoffman-La Roche AG

            14.3.7.1. Company Overview

            14.3.7.2. Product Portfolio

            14.3.7.3. SWOT Analysis

            14.3.7.4. Financial Overview

            14.3.7.5. Strategic Overview

        14.3.8. Akari Therapeutics PLC

            14.3.8.1. Company Overview

            14.3.8.2. Product Portfolio

            14.3.8.3. SWOT Analysis

            14.3.8.4. Financial Overview

            14.3.8.5. Strategic Overview

        14.3.9. Omeros Corporation

            14.3.9.1. Company Overview

            14.3.9.2. Product Portfolio

            14.3.9.3. SWOT Analysis

            14.3.9.4. Financial Overview

            14.3.9.5. Strategic Overview

        14.3.10. Regeneron Pharmaceuticals, Inc.

            14.3.10.1. Company Overview

            14.3.10.2. Product Portfolio

            14.3.10.3. SWOT Analysis

            14.3.10.4. Financial Overview

            14.3.10.5. Strategic Overview

List of Tables

Table 01: Global Paroxysmal Nocturnal Hemoglobinuria Market Size (US$ Bn) Forecast, by Treatment, 2020-2034

Table 02: Global Paroxysmal Nocturnal Hemoglobinuria Market Size (US$ Bn) Forecast, by End-user, 2020-2034

Table 03: Global Paroxysmal Nocturnal Hemoglobinuria Market Size (US$ Bn) Forecast, by Region, 2020-2034

Table 04: North America Paroxysmal Nocturnal Hemoglobinuria Market Size (US$ Bn) Forecast, by Country, 2020-2034

Table 05: North America Paroxysmal Nocturnal Hemoglobinuria Market Size (US$ Bn) Forecast, by Treatment, 2020-2034

Table 06: North America Paroxysmal Nocturnal Hemoglobinuria Market Size (US$ Bn) Forecast, by End-user, 2020-2034

Table 07: Europe Paroxysmal Nocturnal Hemoglobinuria Market Size (US$ Bn) Forecast, by Country/Sub-region, 2020-2034

Table 08: Europe Paroxysmal Nocturnal Hemoglobinuria Market Size (US$ Bn) Forecast, by Treatment, 2020-2034

Table 09: Europe Paroxysmal Nocturnal Hemoglobinuria Market Size (US$ Bn) Forecast, by End-user, 2020-2034

Table 10: Asia Pacific Paroxysmal Nocturnal Hemoglobinuria Market Size (US$ Bn) Forecast, by Country/Sub-region, 2020-2034

Table 11: Asia Pacific Paroxysmal Nocturnal Hemoglobinuria Market Size (US$ Bn) Forecast, by Treatment, 2020-2034

Table 12: Asia Pacific Paroxysmal Nocturnal Hemoglobinuria Market Size (US$ Bn) Forecast, by End-user, 2020-2034

Table 13: Latin America Paroxysmal Nocturnal Hemoglobinuria Market Size (US$ Bn) Forecast, by Country/Sub-region, 2020-2034

Table 14: Latin America Paroxysmal Nocturnal Hemoglobinuria Market Size (US$ Bn) Forecast, by Treatment, 2020-2034

Table 15: Latin America Paroxysmal Nocturnal Hemoglobinuria Market Size (US$ Bn) Forecast, by End-user, 2020-2034

Table 16: Middle East & Africa Paroxysmal Nocturnal Hemoglobinuria Market Size (US$ Bn) Forecast, by Country/Sub-region, 2020-2034

Table 17: Middle East & Africa Paroxysmal Nocturnal Hemoglobinuria Market Size (US$ Bn) Forecast, by Treatment, 2020-2034

Table 18: Middle East & Africa Paroxysmal Nocturnal Hemoglobinuria Market Size (US$ Bn) Forecast, by End-user, 2020-2034

List of Figures

Figure 01: Global Paroxysmal Nocturnal Hemoglobinuria Market Size (US$ Bn) and Distribution (%), by Region, 2023 and 2034

Figure 02: Global Paroxysmal Nocturnal Hemoglobinuria Market Revenue (US$ Bn), by Treatment, 2023

Figure 03: Global Paroxysmal Nocturnal Hemoglobinuria Market Value Share, by Treatment, 2023

Figure 04: Global Paroxysmal Nocturnal Hemoglobinuria Market Revenue (US$ Bn), by End-user, 2023

Figure 05: Global Paroxysmal Nocturnal Hemoglobinuria Market Value Share, by End-user, 2023

Figure 06: Global Paroxysmal Nocturnal Hemoglobinuria Market Value Share, by Region, 2023

Figure 07: Global Paroxysmal Nocturnal Hemoglobinuria Market Value (US$ Bn) Forecast, 2020-2034

Figure 08: Global Paroxysmal Nocturnal Hemoglobinuria Market Value Share Analysis, by Treatment, 2023 and 2034

Figure 09: Global Paroxysmal Nocturnal Hemoglobinuria Market Attractiveness Analysis, by Treatment, 2020-2034

Figure 10: Global Paroxysmal Nocturnal Hemoglobinuria Market Value Share Analysis, by End-user, 2023 and 2034

Figure 11: Global Paroxysmal Nocturnal Hemoglobinuria Market Attractiveness Analysis, by End-user, 2020-2034

Figure 12: Global Paroxysmal Nocturnal Hemoglobinuria Market Value Share Analysis, by Region, 2023 and 2034

Figure 13: Global Paroxysmal Nocturnal Hemoglobinuria Market Attractiveness Analysis, by Region, 2020-2034

Figure 14: North America Paroxysmal Nocturnal Hemoglobinuria Market Value (US$ Bn) Forecast and Y-o-Y Growth (%), 2020-2034

Figure 15: North America Paroxysmal Nocturnal Hemoglobinuria Market Attractiveness Analysis, by Country, 2020-2034

Figure 16: North America Paroxysmal Nocturnal Hemoglobinuria Market Value Share Analysis, by Country, 2023 and 2034

Figure 17: North America Paroxysmal Nocturnal Hemoglobinuria Market Value Share Analysis, by Treatment, 2023 and 2034

Figure 18: North America Paroxysmal Nocturnal Hemoglobinuria Market Value Share Analysis, by End-user, 2023 and 2034

Figure 19: North America Paroxysmal Nocturnal Hemoglobinuria Market Attractiveness Analysis, by Treatment, 2020-2034

Figure 20: North America Paroxysmal Nocturnal Hemoglobinuria Market Attractiveness Analysis, by End-user, 2020-2034

Figure 21: Europe Paroxysmal Nocturnal Hemoglobinuria Market Value (US$ Bn) Forecast and Y-o-Y Growth (%), 2020-2034

Figure 22: Europe Paroxysmal Nocturnal Hemoglobinuria Market Attractiveness Analysis, by Country/Sub-region, 2020-2034

Figure 23: Europe Paroxysmal Nocturnal Hemoglobinuria Market Value Share Analysis, by Country/Sub-region, 2023 and 2034

Figure 24: Europe Paroxysmal Nocturnal Hemoglobinuria Market Value Share Analysis, by Treatment, 2023 and 2034

Figure 25: Europe Paroxysmal Nocturnal Hemoglobinuria Market Value Share Analysis, by End-user, 2023 and 2034

Figure 26: Europe Paroxysmal Nocturnal Hemoglobinuria Market Attractiveness Analysis, by Treatment, 2020-2034

Figure 27: Europe Paroxysmal Nocturnal Hemoglobinuria Market Attractiveness Analysis, by End-user, 2020-2034

Figure 28: Asia Pacific Paroxysmal Nocturnal Hemoglobinuria Market Value (US$ Bn) Forecast and Y-o-Y Growth (%), 2020-2034

Figure 29: Asia Pacific Paroxysmal Nocturnal Hemoglobinuria Market Attractiveness Analysis, by Country/Sub-region, 2020-2034

Figure 30: Asia Pacific Paroxysmal Nocturnal Hemoglobinuria Market Value Share Analysis, by Country/Sub-region, 2023 and 2034

Figure 31: Asia Pacific Paroxysmal Nocturnal Hemoglobinuria Market Value Share Analysis, by Treatment, 2023 and 2034

Figure 32: Asia Pacific Paroxysmal Nocturnal Hemoglobinuria Market Value Share Analysis, by End-user, 2023 and 2034

Figure 33: Asia Pacific Paroxysmal Nocturnal Hemoglobinuria Market Attractiveness Analysis, by Treatment, 2020-2034

Figure 34: Asia Pacific Paroxysmal Nocturnal Hemoglobinuria Market Attractiveness Analysis, by End-user, 2020-2034

Figure 35: Latin America Paroxysmal Nocturnal Hemoglobinuria Market Value (US$ Bn) Forecast and Y-o-Y Growth (%), 2020-2034

Figure 36: Latin America Paroxysmal Nocturnal Hemoglobinuria Market Attractiveness Analysis, by Country/Sub-region, 2020-2034

Figure 37: Latin America Paroxysmal Nocturnal Hemoglobinuria Market Value Share Analysis, by Country/Sub-region, 2023 and 2034

Figure 38: Latin America Paroxysmal Nocturnal Hemoglobinuria Market Value Share Analysis, by Treatment, 2023 and 2034

Figure 39: Latin America Paroxysmal Nocturnal Hemoglobinuria Market Value Share Analysis, by End-user, 2023 and 2034

Figure 40: Latin America Paroxysmal Nocturnal Hemoglobinuria Market Attractiveness Analysis, by Treatment, 2020-2034

Figure 41: Latin America Paroxysmal Nocturnal Hemoglobinuria Market Attractiveness Analysis, by End-user, 2020-2034

Figure 42: Middle East & Africa Paroxysmal Nocturnal Hemoglobinuria Market Size (US$ Bn) Forecast and Y-o-Y Growth (%), 2020-2034

Figure 43: Middle East & Africa Paroxysmal Nocturnal Hemoglobinuria Market Attractiveness Analysis, by Country/Sub-region, 2020-2034

Figure 44: Middle East & Africa Paroxysmal Nocturnal Hemoglobinuria Market Value Share Analysis, by Country/Sub-region, 2023 and 2034

Figure 45: Middle East & Africa Paroxysmal Nocturnal Hemoglobinuria Market Value Share Analysis, by Treatment, 2023 and 2034

Figure 46: Middle East & Africa Paroxysmal Nocturnal Hemoglobinuria Market Value Share Analysis, by End-user, 2023 and 2034

Figure 47: Middle East & Africa Paroxysmal Nocturnal Hemoglobinuria Market Attractiveness Analysis, by Treatment, 2020-2034

Figure 48: Middle East & Africa Paroxysmal Nocturnal Hemoglobinuria Market Attractiveness Analysis, by End-user, 2020-2034

Copyright © Transparency Market Research, Inc. All Rights reserved